Esophageal cancer metabolite biomarkers detected by LC-MS and NMR methods

PLoS ONE

Volumn 7, Issue 1, 2012, Pages

  Zhang, Jian ^a   Bowers, Jeremiah ^a   Liu, Lingyan ^b   Wei, Siwei ^a   Gowda, G A Nagana ^a   Hammoud, Zane ^c   Raftery, Daniel ^a  

^a PURDUE UNIVERSITY   (United States)

^b PURDUE UNIVERSITY   (United States)

^c HENRY FORD HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 HYDROXYBUTYRIC ACID; 5 HYDROXYTRYPTOPHAN; ALANINE; AMINO ACID; CARNITINE; CITRIC ACID; CREATININE; GLUCOSE; GLUTAMIC ACID; GLUTAMINE; HEPTADECANOIC ACID; HISTIDINE; ISOLEUCINE; LACTIC ACID; LEUCINE; LINOLEIC ACID; LINOLENIC ACID; LYSINE; METHIONINE; MYRISTIC ACID; PROLINE; PYROGLUTAMIC ACID; TRYPTOPHAN; TUMOR MARKER; TYROSINE; VALINE;

AMINO ACID ANALYSIS; ARTICLE; CANCER PROGNOSIS; CANCER RISK; CONTROLLED STUDY; DYSPLASIA; ENERGY METABOLISM; ESOPHAGEAL ADENOCARCINOMA; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HIGH RISK POPULATION; HUMAN; MASS SPECTROMETRY; METABOLIC CAPACITY; METABOLITE; NUCLEAR MAGNETIC RESONANCE; SEROLOGY; ADENOCARCINOMA; BARRETT ESOPHAGUS; BLOOD; CASE CONTROL STUDY; EARLY DIAGNOSIS; ESOPHAGUS TUMOR; EVALUATION; FEMALE; LIQUID CHROMATOGRAPHY; MALE; METABOLISM; METABOLOME; METHODOLOGY; PATHOLOGY; RECEIVER OPERATING CHARACTERISTIC; VALIDATION STUDY;

ADENOCARCINOMA; BARRETT ESOPHAGUS; CASE-CONTROL STUDIES; CHROMATOGRAPHY, LIQUID; EARLY DETECTION OF CANCER; ESOPHAGEAL NEOPLASMS; FEMALE; HUMANS; MALE; MASS SPECTROMETRY; METABOLOME; NUCLEAR MAGNETIC RESONANCE, BIOMOLECULAR; ROC CURVE; TUMOR MARKERS, BIOLOGICAL;

EID: 84856118098     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0030181     Document Type: Article

References (41)

1. Jemal A, Siegel R, Xu J, Ward E, (2010) Cancer statistics, 2010. CA Cancer J Clin 60: 277-300.
2. Greenlee RT, Murray T, Bolden S, Wingo PA, (2000) Cancer statistics, 2000. CA Cancer J Clin 50: 7-33.
3. Lagergren J, Bergstrom R, Lindgren A, Nyren O, (1999) Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med 340: 825-831.
4. Waxman I, Raju GS, Critchlow J, Antonioli DA, Spechler SJ, (2006) High-frequency probe ultrasonography has limited accuracy for detecting invasive adenocarcinoma in patients with Barrett's esophagus and high-grade dysplasia or intramucosal carcinoma: a case series. Am J Gastroenterol 101: 1773-1779.
5. Yousef F, Cardwell C, Cantwell MM, Galway K, Johnston BT, et al. (2008) The incidence of esophageal cancer and high-grade dysplasia in Barrett's esophagus: a systematic review and meta-analysis. Am J Epidemiol 168: 237-249.
6. Margulies C, Kim R, Reynolds JC, (1996) Early detection and management of esophageal cancer. Compr Ther 22: 565-578.
7. Chen LQ, Hu CY, Ghadirian P, Duranceau A, (1999) Early detection of esophageal squamous cell carcinoma and its effects on therapy: an overview. Dis Esophagus 12: 161-167.
8. May A, Ell C, (2006) Diagnosis and treatment of early esophageal cancer. Curr Opin Gastroenterol 22: 433-436.
9. McCann P, Stafinski T, Wong C, Menon D, (2011) The safety and effectiveness of endoscopic and non-endoscopic approaches to the management of early esophageal cancer: A systematic review. Cancer Treatment Reviews 37: 11-62.
10. Duffy MJ, Crown J, (2008) A personalized approach to cancer treatment: how biomarkers can help. Clin Chem 54: 1770-1779.
11. Tew WP, Kelsen DP, Ilson DH, (2005) Targeted therapies for esophageal cancer. Oncologist 10: 590-601.
12. Ekman S, Bergqvist M, Heldin CH, Lennartsson J, (2007) Activation of growth factor receptors in esophageal cancer-implications for therapy. Oncologist 12: 1165-1177.
13. van Baal JW, Krishnadath KK, (2008) High throughput techniques for characterizing the expression profile of Barrett's esophagus. Dis Esophagus 21: 634-640.
14. Wang DH, Souza RF, (2011) Biology of Barrett's esophagus and esophageal adenocarcinoma. Gastrointest Endosc Clin N Am 21: 25-38.
15. Guo W, Jiang YG, (2009) Current gene expression studies in esophageal carcinoma. Curr Genomics 10: 534-539.
16. Nicholson JK, Lindon JC, Holmes E, (1999) 'Metabonomics': understanding the metabolic responses of living systems to pathophysiological stimuli via multivariate statistical analysis of biological NMR spectroscopic data. Xenobiotica 29: 1181-1189.
17. Gowda GA, Zhang S, Gu H, Asiago V, Shanaiah N, et al. (2008) Metabolomics-based methods for early disease diagnostics. Expert Rev Mol Diagn 8: 617-633.
18. Pan Z, Raftery D, (2007) Comparing and combining NMR spectroscopy and mass spectrometry in metabolomics. Anal Bioanal Chem 387: 525-527.
19. Spratlin JL, Serkova NJ, Eckhardt SG, (2009) Clinical applications of metabolomics in oncology: a review. Clin Cancer Res 15: 431-440.
20. Sreekumar A, Poisson LM, Rajendiran TM, Khan AP, Cao Q, et al. (2009) Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature 457: 910-914.
21. Asiago VM, Alvarado LZ, Shanaiah N, Gowda GA, Owusu-Sarfo K, et al. (2010) Early detection of recurrent breast cancer using metabolite profiling. Cancer Res 70: 8309-8318.
22. Thysell E, Surowiec I, Hornberg E, Crnalic S, Widmark A, et al. (2010) Metabolomic characterization of human prostate cancer bone metastases reveals increased levels of cholesterol. PLoS One 5: e14175.
23. Tiziani S, Lopes V, Gunther UL, (2009) Early stage diagnosis of oral cancer using 1H NMR-based metabolomics. Neoplasia 11: 269-276.
24. Yakoub D, Keun HC, Goldin R, Hanna GB, (2010) Metabolic profiling detects field effects in nondysplastic tissue from esophageal cancer patients. Cancer Res 70: 9129-9136.
25. Wu H, Xue R, Lu C, Deng C, Liu T, et al. (2009) Metabolomic study for diagnostic model of oesophageal cancer using gas chromatography/mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 877: 3111-3117.
26. Ayxiam H, Ma H, Ilyar S, Zhang LW, Ablizi A, et al. (2009) Metabonomic variation of esophageal cancer within different ethnic groups in Xinjiang, China. Zhonghua Yu Fang Yi Xue Za Zhi 43: 591-596.
27. Zhang J, Liu L, Wei S, Nagana Gowda GA, Hammoud Z, et al. (2011) Metabolomics study of esophageal adenocarcinoma. J Thorac Cardiovasc Surg 141: 469-475, 475 e461-464.
28. Djukovic D, Baniasadi HR, Kc R, Hammoud Z, Raftery D, (2010) Targeted serum metabolite profiling of nucleosides in esophageal adenocarcinoma. Rapid Commun Mass Spectrom 24: 3057-3062.
29. Nicholson JK, Foxall PJ, Spraul M, Farrant RD, Lindon JC, (1995) 750 MHz 1H and 1H-13C NMR spectroscopy of human blood plasma. Anal Chem 67: 793-811.
30. Human Metabolome Database website. Available: http://www.hmdb.ca. Accessed 2011 Dec 30.
31. Madison-Qingdao Metabolomics Consortium Database website. Available: http://mmcd.nmrfam.wisc.edu. Accessed 2011 Dec 30.
32. Walenta S, Schroeder T, Mueller-Klieser W, (2004) Lactate in solid malignant tumors: potential basis of a metabolic classification in clinical oncology. Curr Med Chem 11: 2195-2204.
33. Lai HS, Lee JC, Lee PH, Wang ST, Chen WJ, (2005) Plasma free amino acid profile in cancer patients. Semin Cancer Biol 15: 267-276.
34. Denkert C, Budczies J, Weichert W, Wohlgemuth G, Scholz M, et al. (2008) Metabolite profiling of human colon carcinoma-deregulation of TCA cycle and amino acid turnover. Mol Cancer 7: 72.
35. Qiu Y, Cai G, Su M, Chen T, Zheng X, et al. (2009) Serum metabolite profiling of human colorectal cancer using GC-TOFMS and UPLC-QTOFMS. J Proteome Res 8: 4844-4850.
36. Lean CL, Newland RC, Ende DA, Bokey EL, Smith IC, et al. (1993) Assessment of human colorectal biopsies by 1H MRS: correlation with histopathology. Magn Reson Med 30: 525-533.
37. Qiu Y, Cai G, Su M, Chen T, Liu Y, et al. (2010) Urinary metabonomic study on colorectal cancer. J Proteome Res 9: 1627-1634.
38. Wang H, Tso VK, Slupsky CM, Fedorak RN, (2010) Metabolomics and detection of colorectal cancer in humans: a systematic review. Future Oncol 6: 1395-1406.
39. Boros LG, (2005) Metabolic targeted therapy of cancer: current tracer technologies and future drug design strategies in the old metabolic network. Metabolomics 1: 11-15.
40. Greg Maguire PL, David Manheim, Laszlo Boros, (2006) SiDMAP: a metabolomics approach to assess the effects of drug candidates on the dynamic properties of biochemical pathways. Expert Opinion on Drug Discovery 1: 351-359.
41. Fan TW, Lane AN, (2011) NMR-based stable isotope resolved metabolomics in systems biochemistry. J Biomol NMR 49: 267-280.